KRAS and breast carcinoma: In this context, synthetic peptide inhibitors with submicromolar binding affinity to mutant KRAS have been used to inhibit the PPI between the intracellular RAS and its downstream signaling partner rapidly accelerated fibrosarcoma (RAF), suggesting a potential therapeutic strategy for breast cancer.